![](/images/graphics-bg.png)
Aplasia in Chronic Phase CML Post-TKI Therapy: A Management Dilemma
Joint Authors
Ramdial, Jeremy L.
Aguirre, Luis E.
Ali, Robert A.
Swords, Ronan
Goodman, Mark
Source
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-7, 7 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-09-22
Country of Publication
Egypt
No. of Pages
7
Main Subjects
Abstract EN
Transient cytopenias and bone marrow hypoplasia commonly occur during treatment of CML with TKIs (tyrosine kinase inhibitors).
This is usually related to the eradication of CML clones that initially compose the majority of hematopoietic cells in the bone marrow at the time of diagnosis.
With continuation of effective therapy, normal blood counts return as normal hematopoiesis is restored and CML clones are reduced.
Though rare and more unusual than myelodysplastic syndrome (MDS), isolated instances of persistent marrow aplasia have been documented with chronic use of TKIs.
We describe two such instances of chronic phase CML where no significant reduction of CML clones was achieved following treatment with TKIs, but bone marrow aplasia occurred resulting in persistent dysfunctional hematopoiesis.
Due to prolonged aplasia/hypoplasia, such patients are no longer amenable to TKI treatment.
CML progression to accelerated or blast phase in that setting would likely be fatal.
American Psychological Association (APA)
Ramdial, Jeremy L.& Aguirre, Luis E.& Ali, Robert A.& Swords, Ronan& Goodman, Mark. 2019. Aplasia in Chronic Phase CML Post-TKI Therapy: A Management Dilemma. Case Reports in Hematology،Vol. 2019, no. 2019, pp.1-7.
https://search.emarefa.net/detail/BIM-1136603
Modern Language Association (MLA)
Ramdial, Jeremy L.…[et al.]. Aplasia in Chronic Phase CML Post-TKI Therapy: A Management Dilemma. Case Reports in Hematology No. 2019 (2019), pp.1-7.
https://search.emarefa.net/detail/BIM-1136603
American Medical Association (AMA)
Ramdial, Jeremy L.& Aguirre, Luis E.& Ali, Robert A.& Swords, Ronan& Goodman, Mark. Aplasia in Chronic Phase CML Post-TKI Therapy: A Management Dilemma. Case Reports in Hematology. 2019. Vol. 2019, no. 2019, pp.1-7.
https://search.emarefa.net/detail/BIM-1136603
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1136603